Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 70.05
+2.00 (2.94%)
Oct 27, 2026, 12:19 PM CET
Pharma Mar Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Pharma Mar stock has a consensus rating of "Buy" and an average price target of €102.44. The average 1-year stock price forecast is 46.24% higher than the current stock price, while the lowest is €85.50 (+22.06%) and the highest is €125.00 (+78.44%).
Price Target: €102.44 (+46.24%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Aug 10, 2026.
Analyst Ratings
The average analyst rating for Pharma Mar stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Maintains €100.00 | Buy | Maintains | €100.00 | +42.76% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
214.84M
from 221.39M
Decreased by -2.96%
Revenue Next Year
313.37M
from 214.84M
Increased by 45.86%
EPS This Year
2.00
from 4.30
Decreased by -53.39%
EPS Next Year
5.49
from 2.00
Increased by 173.75%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.